Innocan Pharma Corp
OTC:INNPF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Innocan Pharma Corp
Operating Income
Innocan Pharma Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Innocan Pharma Corp
CNSX:INNO
|
Operating Income
-$1.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$4.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$25.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-2%
|
|
|
P
|
Purple Biotech Ltd
TASE:PPBT
|
Operating Income
-$7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-6%
|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Operating Income
-$6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
|
|
T
|
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
|
Operating Income
-₪19.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Innocan Pharma Corp
Glance View
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
See Also
What is Innocan Pharma Corp's Operating Income?
Operating Income
-1.3m
USD
Based on the financial report for Dec 31, 2025, Innocan Pharma Corp's Operating Income amounts to -1.3m USD.
What is Innocan Pharma Corp's Operating Income growth rate?
Operating Income CAGR 5Y
23%
Over the last year, the Operating Income growth was -1%. The average annual Operating Income growth rates for Innocan Pharma Corp have been 41% over the past three years , 23% over the past five years .
